



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 152030

TO: Rebecca Cook
Location: rem/3a71/3c70
Art Unit: 1614
Friday, April 29, 2005

Case Serial Number: 10/780553

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

SEARCH REQUEST FORM

Scientific and Technical Information Center

APR 29 2005

Requester's Full Name: Rebecca Cook Examiner #: 69826 Date: 4/28/05
 Art Unit: 1614 Phone Number 30 15110 Serial Number: 701 780 533
 Mail Box and Bldg/Room Location: 3C70 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. 3471 MEJ

 Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please do litigation search for
6,239,118. It is a re-exam

Thank you

Rebecca

Rush Search Approved
TK Page
SPE, AUG 15

STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Noble</u>	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit <u>11</u>
Date Searcher Picked Up: _____	Bibliographic <u>/</u>	Dr. Link _____
Date Completed: <u>4/29/05</u>	Litigation <u>/</u>	Lexis/Nexis _____
Searcher Prep. Review Time: <u>5</u>	Fulltext _____	Sequence Systems _____
Clerical Prep. Time: _____	Patent Family _____	WWW/Internet _____
Online Time <u>5</u>	Other _____	Other (specify) _____

?file pluspat

QUESTEL

Selected file: PLUSPAT

PLUSPAT - (c) Questel-Orbit, All Rights Reserved.
 Comprehensive Worldwide Patents database
 New Patent Citation Commands & FAM Citation Report - see INFO PATCITE
 Announcing enhanced searchability of Relevancy Codes in Search Reports
 for EP, WO and FR patents. For more details see below and on QO website
 -To retrieve set of high relevancy X coded cited patents, use xctx=yes
 -To extract cited patents with only high relevancy code, use mem/xctx
 Last update of file: 2005/04/27 (YYYY/MM/DD) 2005-16/UP (last update)

Search statement 1

?us6239118/pn

** SS 1: Results 1

Search statement 2

?prt full legalall max

1/1 PLUSPAT - (C) QUESTEL-ORBIT
 PN - US6239118 B1 20010529 [US6239118]
 TI - (B1) Method for preventing restenosis using a substituted adenine
 derivative
 IN - (B1) SAVEN ALAN (US); SCHATZ RICHARD A (US)
 AP - US41241899 19991005 [1999US-0412418]
 PR - US41241899 19991005 [1999US-0412418]
 IC - (B1) A61K-031/70
 EC - A61K-031/70R10P10
 PCL - ORIGINAL (O) : 514045000; CROSS-REFERENCE (X) : 514046000
 DT - Basic
 CT - US5106837; US5424296; US5510336
 - Libby et al, Nouv Rev Fr Hematol, 34 Suppl. S47-53, 1992.*

Faxon, David P., M.D., Chronic Inflammation, Clinical Trials and Remodeling; pp. 136-138; University of Southern California School of Medicine, Los Angeles, CA; Restenosis Summit VIII, 1996.

Gerrity, Ross G., PhD. The Role of the Monocyte in Atherogenesis, pp. 181 and 191; Research Division, The Cleveland Clinic Foundation, Cleveland, Ohio, Nov. 1, 1980.

Leibovich, S. J. PhD. et al., A Macrophage-Dependent Factor That Stimulates the Proliferation of Fibroblasts in Vitro; American Journal of Pathology; pp. 501, 508, and 511; Department of Pathology, University of Washington School of Medicine, Seattle, Washington, Apr. 23, 1976.

Ross, Russell, PhD., Mechanism of Disease Atherosclerosis--An Inflammatory Disease, The New England Journal of Medicine vol. 340, No. 2, pp. 115-126; Department of Pathology, University of Washington School of Medicine, Seattle, Washington; Jan. 14, 1999.

Ross, Russell, PhD. Medical Progress; The Pathogenesis of Atherosclerosis--An Update; The New England Journal of Medicine vol. 314, No. 8, pp. 488, 493, 494; Department of Pathology, University of Washington School of Medicine, Seattle, Washington; Feb. 20, 1986.

Saven, Alan, M.D., et al.; Brief Communications, 2-Chlorodeoxyadenosine-induced Complete Remissions in Langerhans-Cell Histiocytosis, pp. 430-432; Reprinted from Annals of Internal Medicine, vol. 121, No. 6, Sep. 15, 1994.

Schwartz, Stephen M., et al; Remodeling: How Vessels Narrow, Clinical

Trials and Remodeling; pp. 128-131; University of Washington, Seattle, WA; Massachusetts General Hospital, Boston, MA; and ZymoGenetics, Inc., Seattle WA. 1996.

Waltenberger, Johannes, M.D., Current Perspectives, Modulation of Growth Factor Action, Implications for the Treatment of Cardiovascular Diseases; Circulation, pp. 4083-4094; vol. 96, No. 11, Department of Internal Medicine II (Cardiology); Ulm University Medical Center, Ulm, Germany; Dec. 2, 1997.

Copy of Brochure for Leustatin® (cladribine) Injection; Ortho Biotech, Raritan, New Jersey, Dec. 1996.

STG - (B1) U.S. Patent (no pre-grant pub.) after Jan. 2, 2001

AB - The present invention discloses a method for the prevention of atherosclerosis, its genesis, progression and restenosis in human patients undergoing treatments for arterial lesions such as PTA or atherectomy, and which may be accompanied by stent implantation. Further, the treatment method disclosed has applicability in all stages of atherosclerosis in which monocytes play a role. The compound utilized in the present method as the active agent is a 2-halo-2'-deoxyadenosine such as 2-chloro-deoxyadenosine (2-CdA). The treatment method of the present invention includes the administration of 14 doses of 2-CdA in the amount of 0.12 mg/kg. One dose is given intravenously before the coronary intervention, another is given intravenously after the intervention and the remaining twelve doses are given subcutaneously at weekly intervals over a subsequent three month period.

UP - 2001-24

1/1 LGST - (C) EPO

PN - US6239118 B1 20010529 [US6239118]

AP - US41241899 19991005 [1999US-0412418]

ACT - 20040727 US/RF-A

REISSUE APPLICATION FILED

EFFECTIVE DATE: 20040218

UP - 2004-34

1/1 CRXX - (C) CLAIMS/RRX

AN - 3518593

PN - 6,239,118 A 20010529 [US6239118]

PA - Saven, Alan; Schatz, Richard A

PT - C (Chemical)

ACT - 20040218 REISSUE REQUESTED

ISSUE DATE OF O.G. : 20040727

REISSUE REQUEST NUMBER: 10/780553

EXAMINATION GROUP RESPONSIBLE FOR REISSUEPROCESS: 1614

Reissue Patent Number:

UP - 2004-31

UACT- 2004-07-27

Search statement 2

?

LexisNexis CourtLink

[Order Documents](#) | [Available Courts](#) | [Lexis.com](#) | [Sign Out](#) | [Help](#)

Welcome Noble Jarrell!

[My CourtLink](#) | [Search](#) | [Dockets & Documents](#) | [Track](#) | [Alert](#) | [Strategic Profiles](#) | [My Account](#)[Search](#) > Patent Search

Cancel



Patent Number Search

Enter a Patent Number or Select a District Court

- Entering a patent number displays all cases related to that patent.
- Selecting a Court displays all patent-related cases for that court.

Enter a Patent Number [\[info\]](#)

6,239,118

-- OR --

Select a District Court

-- Select --

Client Matter Code: [\[info\]](#)Previous Codes: [\[info\]](#)

-- Select One --

[Manage Previous Codes](#)

These codes will appear on your invoice next to charges associated with this search. The values will be preserved until changed.

Client/Project Notes:

Cancel

[Pricing](#) | [Privacy](#) | [Master Services Agreement](#)

Copyright © 2005 LexisNexis, a division of Reed Elsevier Inc. All rights reserved.

LexisNexis® CourtLink®

[Order Documents](#) | [Available Courts](#) | [Lexis.com](#) | [Sign Out](#) | [Help](#)

Welcome Noble Jarrell!

[My CourtLink](#) | [Search](#) | [Dockets & Documents](#) | [Track](#) | [Alert](#) | [Strategic Profiles](#) | [My Account](#)[Search](#) > [Patent Search](#) > Searching

Patent Search - Number: 6,239,118



No cases containing this patent number were found.

[Return to Search](#)

(Charges for search still apply)

[Pricing](#) [Privacy](#) [Master Services Agreement](#)[Copyright](#) © 2005 LexisNexis, a division of Reed Elsevier Inc. All rights reserved.



My Lexis™ Search Research Tasks Search Advisor Get a Document Shepard's®

Switch Client Preferences Feedback Sign Off Help
ECLIPSE History

View Printable History

History

Today's Results Archived Activity

Set Filter

1-4 of 4

View Original Results
(until 2 a.m. Eastern Time)

Docs Source/Service

Sort results by
Client ID Date

Re-run/Edit

6239118 or 6,239,118	2	News, All (English, Full Text)	04/29/2005 12:16:21	Re-Run/Edit
6239118 or 6,239,118	0	Patent, Trademark & Copyright Periodicals, Combined	04/29/2005 12:16:04	Re-Run/Edit
6239118 or 6,239,118	0	Patent Cases from Federal Courts and Administrative Materials	04/29/2005 12:15:37	Re-Run/Edit
patno is 6239118	1	Utility, Design and Plant Patents	04/29/2005 12:14:36	Re-Run/Edit
❖				

[My Lexis™](#) | [Search](#) | [Research Tasks](#) | [Search Advisor](#) | [Get a Document](#) | [Shepard's®
Eclipse™](#) | [History](#) | [Delivery Manager](#) | [Switch Client](#) | [Preferences](#) | [Feedback](#) | [Sign Off](#) | [Help](#)
[About LexisNexis](#) | [Terms and Conditions](#)

Copyright © 2005 LexisNexis, a division of Reed Elsevier Inc. All rights reserved.

1 of 1 DOCUMENT

UNITED STATES PATENT AND TRADEMARK OFFICE GRANTED PATENT

6239118

[Link to Claims Section](#)

May 29, 2001

Method for preventing restenosis using a substituted adenine derivative

REISSUE: February 18, 2004 - Reissue Application filed Ex. Gp.: 1614; Re. S.N. 10/780,553 (O.G. July 27, 2004)

APPL-NO: 412418 (09)

FILED-DATE: October 5, 1999

GRANTED-DATE: May 29, 2001